Pfizer Ltd
NSE: PFIZER BSE: 500680
₹5062.20
(-0.57%)
Wed, 11 Mar 2026, 10:24 am
Market Cap231.87B
PE Ratio27.13
Dividend0.69
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1950
- Incorporated as Dumex Ltd on 21 November.
- Manufactures pharmaceuticals, veterinary products, isonicotinic acid hydrazide, PAS acid, Protinex at Mumbai.
- Fermentation plant for antibiotics, synthesis unit at Chandigarh.
1952
- Set up plant at Reay Road, Mumbai for antibiotics, anti-TB, vitamins, nutritional products.
1958
- Pfizer took over the company; name changed to Pfizer (P) Ltd.
1960
- Redeemed 15,000 preference shares.
- Issued 25,100 equity shares.
1963
- Subdivided Rs 100 shares into Rs 10 shares.
1964
- Issued 100,000 equity shares.
1965
- Entered licence agreement with Pfizer Corporation.
- Issued 1,250,000 shares; entire capital held by Pfizer Corporation Panama.
1966
- Issued 660,000 shares at premium of Rs 15: 198,000 to directors/employees, 462,000 to public.
1968
- Called up Rs 2 per share on Capital Account.
- Forfeited 1,800 shares; reissued 180.
- Issued 1,329,100 bonus shares in 1:2 proportion.
1972
- Issued 1,594,568 bonus equity shares in 2:5 proportion.
1977
- Became public limited company on 4 March.
- Issued 4,464,820 bonus shares in 4:5 proportion.
1982
- Issued 1,674,300 equity shares at premium to reduce foreign shareholding to 60%.
1983
- Received consent to issue 537,500 equity shares at premium for manufacturing project.
1985
- Duchem Laboratories and Euphoric Drugs became wholly owned subsidiaries; Euphoric subsidiary of Duchem.
1988
- Pfizer Corp offered 2,344,050 shares for sale to reduce foreign holding to 40%.
- Allotted shares to Euphoric Pharmaceuticals, shareholders, employees, and associates.
1989
- Launched Piroxicam as DOLONEX.
1990
- Launched Distodin for cattle.
- Issued 14% NCDs aggregating Rs 200 lakhs to ICICI.
1991
- Issued 200,000 16.5% redeemable NCDs to ICICI.
1992
- Amalgamated Dumex Ltd effective 1 April.
- Introduced Dolmex injection.
- Launched Coxistac anti-coccidial.
- Ceased to be FERA company.
1995
- Proposed introduction of Gastro Intestinal Therapeutic System.
1996
- Acquired SmithKline Beecham animal healthcare operations.
- Sold bulk drug plant at Kalyani to Dabur.
- Discontinued Combantrin, Diabinese, and two Terramycin forms.
1998
- Launched antihypertensive Amlogard.
- Converted letter of intent for COMBANTRIN and BANMINTH into industrial licence.
- Decided not to manufacture oleandomycin.
1999
- Issued notice to close Ankleshwar manufacturing plant by 31 July.
- FIPB approved 100% subsidiary setup.
- Transferred Magnamycin from Duchem subsidiary.
2000
- Tied up with Shantha Biotechnics for parallel marketing.
- Allotted 1:1 bonus shares, increasing paid-up capital to Rs 23.44 crore.
- Appointed Hocne Sidi Said as Managing Director effective January 2001.
- Accepted resignation of Bhaskar Bhattacharya.
2002
- Completed operational merger with Parke-Davis; legal merger underway.
- Appointed Michael Sweitzer as Director; Kewal Handa as Alternate Director.
2003
- Bombay High Court granted stay on Pfizer-Parke-Davis merger.
- Supreme Court permitted Parke-Davis merger; issued equity shares in 9:4 ratio.
- Appointed Richard Gane as Director.
- Reduced board strength from 11 to 6; appointed Kewal Handa and B M Gagrat as directors.
- Completed operational integration of Pharmacia.
- Appointed Bharat S Raut & Co as auditors.
2004
- Entered co-promotion agreement with Sanofi Synthelabo for Daxid.
- Withdrew Gelusil product.
- Subsidiary tied up with Siro Clinpharm.
2006
- Launched two new products.
2007
- Appointed Yugesh Goutam as Additional Director.
2010
- Entered collaboration with TCG Lifesciences for preclinical molecules.
2011
- Recommended final dividend of Rs. 4.00 per equity share.
2012
- Appointed Aijaz Tobaccowalla as Managing Director.
- Recommended dividend of Rs. 12.50 per equity share.
2013
- Announced merger with Wyeth Ltd.
- Won 2.15 billion patent lawsuit against Teva and Sun Pharmaceutical.
2015
- Completed acquisition of Hospira, Inc.
- Agreed to transfer Thane plant business to Vidhi Research.
- Shifted Registered Office to The Capital, Bandra Kurla Complex, Mumbai.
- Entered definitive merger agreement with Allergan.
- Announced ‘Innovation and IP Program’ with IIT Delhi.
2016
- Acquired Treerly from Sirio Pharma.
2017
- Acquired AstraZeneca’s Neksium for INR 750 million.
2018
- Entered ICMR partnership on Antimicrobial Resistance.
2021
- Pfizer and BioNTech finalized agreement to supply 200 million COVID-19 vaccine doses to EU.
2022
- Launched ‘Pfizer PAP India’ assistance app.
- Launched Project Aastha Cancer-Care Services and Helpdesk at Sawai Man Singh Hospital, Jaipur.
- Partnered with Father Muller Research to strengthen evidence generation.
- Partnered with Max Super Speciality Hospitals.
- Set up global drug development center in India.
2023
- Entered into agreement to assign lease of MIDC land and sell building.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800